TOG Review (RCOG Journal)

MRCOG Part 2

Gynaecological Oncology

Endometriosis as a risk factor for ovarian cancer

Key Statistics

  • 1 in 10 — Premenopausal women with endometriosis (UK)
  • 2% → 4% — Lifetime EOC risk without vs with endometriosis
  • RR 2.46 — EOC risk with ovarian endometriosis (Saavalainen)

Don't-miss facts

  1. Endometriosis roughly doubles lifetime EOC risk (2/100 → 4/100); ESHRE: +1.2% absolute background risk added

  2. EAOC = endometrioid (EC) + clear cell carcinoma (CCC) subtypes

  3. Only ovarian endometriosis (not peritoneal/deep) significantly raises overall EOC risk – RR 2.46 (Saavalainen)

  4. No screening recommended – UKCTOCS and UKFOCS both failed to show mortality benefit

  5. ESHRE does not recommend BSO for EAOC risk reduction (NNH 24 for all-cause mortality)

  6. Tubal ligation gives best EAOC-specific risk reduction (EC RR 0.54, CCC RR 0.55) – offer once family complete

  7. CHC ≥5y use → 20.5% overall EOC risk reduction (21% EC, 27% CCC); protection lasts decades

  8. NICE: PARP inhibitor maintenance for advanced EOC responding to chemo, regardless of BRCA status

Risk reduction – effective vs unproven

Effective: tubal ligation, deep excisional surgery, CHC, DMPA, LNG-IUS

No benefit shown: aspirin, dienogest (no long-term data), BSO not ESHRE-recommended

Abbreviation Key

  • EOC — epithelial ovarian cancer
  • EZH2 — enhancer of zeste homolog 2 (methyltransferase)
  • EAOC — endometriosis-associated ovarian cancer
  • UKCTOCS — UK Collaborative Trial of Ovarian Cancer Screening
  • CCC — clear cell carcinoma
  • UKFOCS — UK Familial Ovarian Cancer Screening Trial
  • EC — endometrioid carcinoma
  • ESHRE — European Society of Human Reproduction and Embryology
  • ARID1A — AT-rich interaction domain 1A (tumour suppressor gene)
  • NICE — National Institute for Health and Care Excellence
  • SWI-SNF — SWItch/Sucrose Non-Fermentable chromatin
  • remodelling complex OS — overall survival
  • DMPA — depot medroxyprogesterone acetate
  • PFS — progression-free survival
  • LNG-IUS — levonorgestrel-releasing intrauterine system
  • DFS — disease-free survival

Source: Campbell R et al. Endometriosis as a risk factor for ovarian cancer: an update on screening, risk reduction, treatment and prognosis. The Obstetrician & Gynaecologist 2024;26:189–196. doi:10.1111/tog.12948

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).

Included with a Pass Package

  • Audio overview of this guideline
  • Practice questions drawn from it
  • AI tutor answers grounded in its text
  • Your own annotations
Start free